Meetings: To be scheduled with conference representatives or directly with Umoja ...

The most comprehensive map of the developing human thymus sheds light on how immune responses are built and maintained at early life, with implications for understanding and treating immunodeficiency, ...

Autoimmunity Biosolutions has closed a seed financing to support its work advancing a next-generation, immuno-corrective therapy for autoimmune diseases. The company’s approach targets a branch of the ...

It’s shocking to see the news that autoimmune conditions are skyrocketing. And 80 percent of cases are in women, according to ...

Large database study finds no increase in mortality, although other endpoints haven’t yet been reported, and the findings ...

Diseases with immune dysregulation occur when the immune system fails to function properly, either by being overactive, underactive, or attacking the body's own tissues. These disorders encompass a ...

The American College of Rheumatology (ACR) 2024 Convergence has just concluded, showcasing significant advancements and ...

Fate Therapeutics driven by positive Phase 1 Autoimmunity study results for its CAR T-cell therapy candidate FT819 in lupus ...

Fate Therapeutics (NASDAQ:FATE) stock rallied 37% Monday after the company reported that the first patient in the Phase 1 ...

Incyte (Nasdaq:INCY) today announced that it will pause enrollment in the ongoing Phase 2 study of MRGPRX2 (INCB000262) in chronic spontaneous urticaria (CSU). The decision was made following the ...

One of the key drivers behind the stock’s impressive jump is the recent presentation of initial clinical and translational data from the company’s ongoing FT819 Phase 1 Autoimmunity study at the ...